AMKR vs MDB

AMKR exhibits exceptional fundamental health with a Piotroski F-Score of 8/9 and a strong liquidity profile (Current Ratio 2.27). However, the stock is currently experiencing a severe valuation disconnect, trading at $78.11—significantly above its Graham Number ($24.70), Intrinsic Value ($44.25), and the average analyst target ($57.25). While explosive earnings growth (61% YoY) and a low PEG ratio (0.76) justify a premium, the massive 1-year price surge of 354% combined with bearish insider selling suggests the stock is overextended. The outlook is a tug-of-war between elite operational performance and an unsustainable valuation multiple.

MDB presents a stable financial health profile with a Piotroski F-Score of 5/9, characterized by exceptional liquidity and minimal debt. While the company demonstrates strong top-line growth (26.7% YoY) and a remarkable track record of earnings beats, it continues to struggle with net profitability (Profit Margin: -2.89%). The outlook is conflicted: strong analyst targets ($354.41) and high gross margins are countered by bearish insider sentiment and a severe short-term technical downtrend.